Reactor produced [64Cu]CuCl2 as a PET radiopharmaceutical for cancer imaging: from radiochemistry laboratory to nuclear medicine clinic.
Rubel ChakravartyPriyalata ShettyK V Vimalnath NairArdhi RajeswariK C JagadeesanHaladhar Dev SarmaVenkatesh RangarajanRahul KrishnatrySudipta ChakrabortyPublished in: Annals of nuclear medicine (2020)
To the best of our knowledge, this is the first study on use of reactor produced [64Cu]CuCl2 for PET imaging of cancer in human patients. It is envisaged that this route of production of 64Cu would aid towards affordable availability of this radioisotope for widespread clinical use in countries with limited cyclotron facilities.
Keyphrases
- pet imaging
- papillary thyroid
- squamous cell
- endothelial cells
- end stage renal disease
- wastewater treatment
- healthcare
- high resolution
- ejection fraction
- computed tomography
- newly diagnosed
- primary care
- positron emission tomography
- lymph node metastasis
- prognostic factors
- metal organic framework
- aqueous solution
- anaerobic digestion
- patient reported outcomes
- mass spectrometry
- induced pluripotent stem cells
- pet ct
- patient reported